Summary
Large cooperative trials are more likely than series studied by small groups to bring about significant progress in the field of intravesical adjuvant chemotherapy of superficial bladder tumor
Multicenter randomized trials involving large numbers of patients have been conducted in Europe by the EORTC Urological Group. The Group's main objectives were to compare the efficacy of thio-TEPA, VM-26, epodyl, Adriamycin, and cisplatin, against no treatment, and to study the prophylactic effect of oral pyridoxine and evaluate the main prognostic factors. The results obtained so far are reported. Preliminary information is also given about the Blinst study, a multicenter open investigation of local chemotherapy with doxorubicin (Adriamycin), with special reference to evaluation of the importance of different modalities of treatment with a single drug.
Similar content being viewed by others
References
Banks MD, Pontes JE, Izbicki RM, Pierce JR Jr (1978) Topical instillation of doxorubicin hydrochloride in the treatment of recurring superficial transitional cell carcinoma of the bladder. J Urol 118: 757
Byar D, Blackard C (1977) Comparisons of placebo, pyridoxine and topical thiotepa in preventing recurrence of stage T1 bladder cancer. Urology 10: 556
Dalesio O, Schulman CC, Sylvester R, De Pauw M, Robinson M, Denis L, Smith PH, Viggiano G, and Members of the EORTC Genito-Urinary Tract Cancer Cooperative Group (1982) Prognostic factors in superficial bladder tumours: a study of the EORTC Genito-Urinary Tract Cancer Cooperative Group. J Urol (in press)
De Pauw M, Bouffioux C, Casselman J, Schulman C, Vergison B, Denis L (1980) The European Organization for Research on Treatment of Cancer. Genito-Urinary Tract Cancer Cooperative Group. Acta Urol Belg 48: 285
Kurth KH, Schroder FH, Tunn U, Denis L, de Pauw M, Sylvester R, and Members of the EORTC Urological Group (1982) Phase-III chemotherapy with adriamycin or epodyl for resected T1 and Ta papillary carcinoma of the bladder. Abstract, presented at the meeting on bladder tumours, Sarasota, Florida, USA
Nieh PT, Daly JJ, Heaney JA, Heney NM, Prout GR Jr (1978) The effect of intravesical Thiotepa on normal and tumor urothelium. J Urol 59: 119
Pavone-Macaluso M (1977) II gruppo cooperativo urologico dell'EORTC. Struttura scopi, ricerche, risultati: In: The tumours of genito-urinary apparatus. Cofese Edizioni, Palermo, p 19
Pavone-Macaluso M, Caramia G (1972) Adriamycin and Daunomycin in the treatment of vesical and prostatic neoplasia. Preliminary results: In: International Symposium on Adriamycin. Springer, Berlin Heidelberg New York, p 180
Pavone-Macaluso M, Ingargiola GB (1980) Local chemotherapy in bladder cancer treatment. Oncology 37: 71
Pavone-Macaluso M, Caramia G, Rizzo FP, Messana V (1975) Preliminary evaluation of VM-26. A new epipodophyllotoxin derivative in the treatment of urogenital tumors. Eur Urol 1: 53
Riddle P (1980) Survival in patients treated with Epodyl (1968–1978) In: bladder tumors and other topics in urological oncology. Plenum Press, New York London, p 333
Schulman CC, Sylvester R, Robinson M, Smith P, Lachand A, Denis L, Pavone-Macaluso M, De Pauw M, Staquet M (1981) Preliminary results from EORTC (European Organization on Research on Cancer) studies for superficial bladder tumours: In: Bladder cancer. Principles of combination therapy. Butterworth, London, p 75
Schulman CC, Robinson M, Denis L, Smith P, Viggiano G, de Pauw M, Dalesio O, Sylvester R, and Members of the EORTC Genito-Urinary Tract Cancer Cooperative Group (1982) Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM-26) and TUR alone. Eur Urol 8: 207
Veenema RJ, Dean AL, Uson AC, Roberts M, Longo F (1969) Thiotepa bladder tumors instillations: Therapy and prophylaxis for superficial bladder tumours. J Urol 101: 711
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pavone-Macaluso, M., Tripi, M. & Ingargiola, G.B. Cooperative studies of chemoprophylaxis after transurethral resection of bladder tumors. Cancer Chemother. Pharmacol. 11 (Suppl 1), S16–S21 (1983). https://doi.org/10.1007/BF00256711
Issue Date:
DOI: https://doi.org/10.1007/BF00256711